Literature DB >> 8647439

Identification of functional and structural amino-acid residues by parsimonious mutagenesis.

R Schier1, R F Balint, A McCall, G Apell, J W Larrick, J D Marks.   

Abstract

For in vitro evolution of protein function, we previously proposed using parsimonious mutagenesis (PM), a technique where mutagenic oligodeoxynucleotides (oligo) are designed to minimize coding sequence redundancy and limit the number of amino acid (aa) residues which do not retain parental structural features. For this work, PM was used to increase the affinity of C6.5, a human single-chain Fv (scFv) that binds the glycoprotein tumor antigen, c-erbB-2. A phage antibody library was created where 19 aa located in three of the heavy (H) and light (L) chain antigen-binding loops (L1, L3 and H2) were simultaneously mutated. After four rounds of selection, 50% of scFv had a lower dissociation rate constant (koff) than the parental scFv. The Kd of these scFv ranged from twofold (Kd=7.0 x 10(-9) M) to sixfold (Kd=2.4 x 10(-9) M) lower than the parental scFv (Kd=1.6 x 10(-8) M). In higher affinity scFv, substitutions occurred at 10/19 of the positions, with 21/28 substitutions occurring at only four positions, two in H2, and one each in L1 and L3. Only the wild type (wt) aa was observed at 9/19 aa. Based on a model of C6.5, seven of the nine conserved aa have a structural role in the variable domain, either in maintaining the main chain conformation of the loop, or in packing on the H-chain variable domain. Two of the conserved aa are solvent exposed, suggesting they may play a critical role in recognition. Thus, PM identified three types of aa: structural aa, functional aa which modulate affinity, and functional aa, which are critical for recognition. Since the sequence space was not completely sampled, higher affinity scFv could be produced by subjecting functional aa which modulate affinity to a higher rate of mutation. Furthermore, PM could prove useful for modifying function in other proteins that belong to structurally related families.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647439     DOI: 10.1016/0378-1119(95)00821-7

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  10 in total

1.  A general method for greatly improving the affinity of antibodies by using combinatorial libraries.

Authors:  Arvind Rajpal; Nurten Beyaz; Lauric Haber; Guido Cappuccilli; Helena Yee; Ramesh R Bhatt; Toshihiko Takeuchi; Richard A Lerner; Roberto Crea
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

2.  Affinity maturation of antibodies assisted by in silico modeling.

Authors:  Rodrigo Barderas; Johan Desmet; Peter Timmerman; Rob Meloen; J Ignacio Casal
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

3.  Scoring functions for computational algorithms applicable to the design of spiked oligonucleotides.

Authors:  L J Jensen; K V Andersen; A Svendsen; T Kretzschmar
Journal:  Nucleic Acids Res       Date:  1998-02-01       Impact factor: 16.971

4.  Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms.

Authors:  F Chen; G M Kuziemko; P Amersdorfer; C Wong; J D Marks; R C Stevens
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

5.  Exploiting cross-reactivity to neutralize two different scorpion venoms with one single chain antibody fragment.

Authors:  Lidia Riaño-Umbarila; Gabriel Contreras-Ferrat; Timoteo Olamendi-Portugal; Citlalli Morelos-Juárez; Gerardo Corzo; Lourival D Possani; Baltazar Becerril
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

6.  Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.

Authors:  P Amersdorfer; C Wong; S Chen; T Smith; S Deshpande; R Sheridan; R Finnern; J D Marks
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

7.  Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin.

Authors:  C Garcia-Rodriguez; I N Geren; J Lou; F Conrad; C Forsyth; W Wen; S Chakraborti; H Zao; G Manzanarez; T J Smith; J Brown; W H Tepp; N Liu; S Wijesuriya; M T Tomic; E A Johnson; L A Smith; J D Marks
Journal:  Protein Eng Des Sel       Date:  2010-12-13       Impact factor: 1.650

8.  Characterization of the conformational epitope of Guy's 13, a monoclonal antibody that prevents Streptococcus mutans colonization in humans.

Authors:  Craig J van Dolleweerd; Daniel Chargelegue; Julian K-C Ma
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

9.  A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy.

Authors:  Angeline X H Goh; Sebastien Bertin-Maghit; Siok Ping Yeo; Adrian W S Ho; Heidi Derks; Alessandra Mortellaro; Cheng-I Wang
Journal:  MAbs       Date:  2014-03-26       Impact factor: 5.857

10.  Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer.

Authors:  Huicheng Liu; Lili Bai; Liu Huang; Na Ning; Lin Li; Yijia Li; Xuejiao Dong; Qiuyang Du; Minghui Xia; Yufei Chen; Likun Zhao; Yanhu Li; Qingwu Meng; Jing Wang; Yaqi Duan; Jie Ming; Andy Qingan Yuan; Xiang-Ping Yang
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.